HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia.

IF 8.8 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Cochrane Database of Systematic Reviews Pub Date : 2025-09-19 DOI:10.1002/14651858.CD014565

Yusuke Saishoji, Saehyeon Kim, Masahiro Banno, Kunihiro Kohmura, Yuki Kataoka, Yasushi Tsujimoto

引用次数: 0

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of HMG-CoA reductase inhibitors (statins) compared with placebo for schizophrenia in adults.

查看原文本刊更多论文

精神分裂症患者的HMG-CoA还原酶抑制剂（他汀类药物）与安慰剂。

目的：这是Cochrane综述（干预）的一个方案。目的如下：评价HMG-CoA还原酶抑制剂（他汀类药物）与安慰剂治疗成人精神分裂症的利与弊。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cochrane Database of Systematic Reviews 医学-医学：内科

CiteScore

10.60

自引率

2.40%

发文量

173

审稿时长

1-2 weeks

期刊介绍： The Cochrane Database of Systematic Reviews (CDSR) stands as the premier database for systematic reviews in healthcare. It comprises Cochrane Reviews, along with protocols for these reviews, editorials, and supplements. Owned and operated by Cochrane, a worldwide independent network of healthcare stakeholders, the CDSR (ISSN 1469-493X) encompasses a broad spectrum of health-related topics, including health services.